Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Annegret Van der Aa"'
Autor:
Jacqueline M. Tarrant, René Galien, Wanying Li, Lovely Goyal, Yang Pan, Rachael Hawtin, Wangshu Zhang, Annegret Van der Aa, Peter C. Taylor
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 1, Pp 173-190 (2020)
Abstract Introduction The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA). We sought to gain insight into the mode of action and immunological effects of filgotinib,
Externí odkaz:
https://doaj.org/article/266d44c74990413788865cf447b06aaf
Autor:
Mark Genovese, Rene Westhovens, Luc Meuleners, Annegret Van der Aa, Pille Harrison, Chantal Tasset, Arthur Kavanaugh
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Abstract Background The aim was to assess patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib during two phase 2b, 24-week, randomized, placebo-controlled studies. Methods Patients with moderate-to-seve
Externí odkaz:
https://doaj.org/article/ed6c8f8a21764ebbbcd4ac04948395eb
Autor:
W Li, Peter C. Taylor, J Tarrant, L Goyal, R. E. Hawtin, Wangshu Zhang, Y Pan, Annegret Van der Aa, Rene Galien
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 1, Pp 173-190 (2020)
Rheumatology and Therapy
Rheumatology and Therapy
Introduction The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA). We sought to gain insight into the mode of action and immunological effects of filgotinib, a JAK1 se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774587eef31e1e5d88f1a79eedd79783
https://doi.org/10.1007/s40744-019-00192-5
https://doi.org/10.1007/s40744-019-00192-5
Publikováno v:
British Journal of Clinical Pharmacology. 84:2779-2789
Aims Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn's disease. The aim of the present study was to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c2c25d15f5d303b31f88d64ee2529a2
https://doi.org/10.1111/bcp.13726
https://doi.org/10.1111/bcp.13726
Autor:
Mykola Stanislavchuk, Frédéric Vanhoutte, Minodora Mazur, Rene Galien, L. Meuleners, Oleksandr Voloshyn, Florence Namour, Annegret Van der Aa, Gerben van ’t Klooster
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Objective JAK inhibitors have shown efficacy in rheumatoid arthritis (RA). We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02f7de209ab9f04a13f6a7cc674af718
https://doi.org/10.1002/art.40186
https://doi.org/10.1002/art.40186
Autor:
Johan Beetens, Rene Galien, Tim Van Kaem, Gerben van ’t Klooster, Frédéric Vanhoutte, Annegret Van der Aa, Florence Namour
Publikováno v:
British Journal of Clinical Pharmacology
Aims Free fatty acids (FFA) can act as direct signalling molecules through activation of several membrane-bound G-protein coupled receptors. The FFA2 receptor (known as GPR43) is activated by short chain fatty acids (SCFA) such as acetate and has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a43217e0fb3bb179408d147cee9de39
https://doi.org/10.1111/bcp.12900
https://doi.org/10.1111/bcp.12900
Autor:
Leonardo Guizzetti, Brian G. Feagan, Claire E Parker, Tanja van Viegen, Annegret Van der Aa, Reena Khanna, Jenny Jeyarajah, William J. Sandborn, Geert R. D'Haens, Guangyong Zou, Niels VandeCasteele, Marjolijn Duijvestein, Vipul Jairath
Publikováno v:
Clinical Gastroenterology and Hepatology. 18:1121-1132.e2
Background & Aims Endoscopy is used to measure activity of Crohn’s disease (CD) and determine eligibility and outcomes of participants in randomized controlled trials of therapeutic agents. We aimed to estimate the rate of response to placebo in tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0007ae25400ffdc2e3f2ab878b99ea00
https://doi.org/10.1016/j.cgh.2019.08.025
https://doi.org/10.1016/j.cgh.2019.08.025
Autor:
R. Besuyen, Philip J. Mease, Dafna D. Gladman, Chantal Tasset, L. Meuleners, Laura C. Coates, Annegret Van der Aa, Rebecca Kunder, Anna Dudek, Joy M Greer, Mykola Stanislavchuk, Philip S. Helliwell, Filip Van den Bosch, P. Harrison, Neelufar Mozaffarian, Anna Rychlewska-Hanczewska, Walid Abi-Saab
The Janus kinase 1 (JAK1) pathway has been implicated in the pathogenesis of psoriatic arthritis. We aimed to investigate the efficacy and safety of filgotinib, a selective JAK1 inhibitor, for the treatment of psoriatic arthritis.The EQUATOR trial wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad0982792732d2fb545eaab72d2dd14
https://ora.ox.ac.uk/objects/uuid:4edadb75-917f-4a51-a319-707d56c296b3
https://ora.ox.ac.uk/objects/uuid:4edadb75-917f-4a51-a319-707d56c296b3
Autor:
L. Meuleners, Chantal Tasset, P. Harrison, Mark C. Genovese, Annegret Van der Aa, Rene Westhovens, Arthur Kavanaugh
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
The aim was to assess patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib during two phase 2b, 24-week, randomized, placebo-controlled studies. Patients with moderate-to-severe active RA and an inadequa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85419fb1c7147bed0b0442334e9c15bf
https://doi.org/10.1186/s13075-018-1541-z
https://doi.org/10.1186/s13075-018-1541-z
Autor:
Florence, Namour, Liesbeth, Fagard, Annegret, Van der Aa, Pille, Harrison, Yan, Xin, Chantal, Tasset
Publikováno v:
British Journal of Clinical Pharmacology
Aims Filgotinib (GS‐6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn's disease. The aim of the present study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6cd2a3dc51c959f9a42c5dd9ba2a7492
https://pubmed.ncbi.nlm.nih.gov/30088677
https://pubmed.ncbi.nlm.nih.gov/30088677